US 12,146,887 B2
Method for assisting prediction of exacerbation of respiratory infection, and device to assist in predicting exacerbation of respiratory infection
Masashi Mizokami, Ichikawa (JP); Masaya Sugiyama, Ichikawa (JP); Norio Ohmagari, Shinjuku-ku (JP); Noriko Kinoshita, Shinjuku-ku (JP); Youichi Takahama, Kobe (JP); and Kazuki Nakabayashi, Kobe (JP)
Assigned to NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE, Tokyo (JP); and SYSMEX CORPORATION, Kobe (JP)
Filed by NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE, Tokyo (JP); and SYSMEX CORPORATION, Kobe (JP)
Filed on Apr. 15, 2021, as Appl. No. 17/231,209.
Claims priority of application No. 2020-073665 (JP), filed on Apr. 16, 2020; and application No. 2020-101833 (JP), filed on Jun. 11, 2020.
Prior Publication US 2021/0325408 A1, Oct. 21, 2021
Int. Cl. G01N 33/564 (2006.01); G01N 33/537 (2006.01); G01N 33/569 (2006.01); G01N 33/68 (2006.01)
CPC G01N 33/6893 (2013.01) [G01N 33/537 (2013.01); G01N 33/56983 (2013.01); G01N 2333/54 (2013.01); G01N 2333/70535 (2013.01); G01N 2333/70596 (2013.01); G01N 2800/122 (2013.01); G01N 2800/125 (2013.01); G01N 2800/50 (2013.01)] 11 Claims
 
1. A method for assisting prediction of exacerbation of a respiratory infection, comprising:
measuring a biomarker in a specimen collected from a subject suffering from the respiratory infection or a subject suspected of having the respiratory infection, wherein the biomarker is one or more of IFNλ3 and CCL17, and a measured value of the biomarker is an index to predict exacerbation of the respiratory infection of the subject,
identifying a subject having the measured value of IFNλ3 greater than or equal to a threshold value corresponding to IFNλ3, and/or the measured value of CCL17 less than a threshold value corresponding to CCL17,
wherein a possibility of exacerbation of the respiratory infection of the subject is suggested to be high if the biomarker is IFNλ3 and the measured value of IFNλ3 is greater than or equal to a threshold value corresponding to IFNλ3, and/or if the biomarker is CCL17 and the measured value of CCL17 is less than a threshold value corresponding to CCL17, and
administering to said subject an antiviral drug, an anti-inflammatory drug or an ACE inhibitor capable of treating the respiratory infection.